JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Boston Scientific Corp.

Avatud

SektorTervishoid

103.4 0.32

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

102.51

Max

103.81

Põhinäitajad

By Trading Economics

Sissetulek

125M

797M

Müük

398M

5.1B

P/E

Sektori keskmine

62.818

34.393

Aktsiakasum

0.75

Kasumimarginaal

15.748

Töötajad

53,000

EBITDA

-848M

364M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+21.16% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

22. okt 2025

Turustatistika

By TradingEconomics

Turukapital

4.7B

158B

Eelmine avamishind

103.08

Eelmine sulgemishind

103.4

Uudiste sentiment

By Acuity

41%

59%

136 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Boston Scientific Corp. Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. juuli 2025, 11:16 UTC

Tulu

Boston Sci 2Q Net Surges, Company Boosts '25 EPS View on Cardiology Demand

23. apr 2025, 12:16 UTC

Tulu
Suurimad hinnamuutused turgudel

Boston Scientific Shares Higher on Rosy Outlook, 1Q Beats

3. märts 2025, 12:35 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5. veebr 2025, 12:23 UTC

Tulu

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

23. juuli 2025, 10:32 UTC

Tulu

Boston Scientific Sees 3Q Sales Up 17%-19%, Organic Sales Up 12%-14% >BSX

23. juuli 2025, 10:31 UTC

Tulu

Boston Scientific Sees 2025 Sales Up 18%-19%, Organic Sales Up 14%-15% >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY EPS $1.89-EPS $1.93 >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific 2Q Organic Sales Up 17.4% >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific 2Q EPS 53c >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific 2Q Sales $5.06B >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific Sees 3Q Adj EPS 70c-Adj EPS 72c >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific 2Q Adj EPS 75c >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY Adj EPS $2.95-Adj EPS $2.99 >BSX

23. juuli 2025, 10:30 UTC

Tulu

Boston Scientific Sees 3Q EPS 44c-EPS 46c >BSX

23. apr 2025, 10:32 UTC

Tulu

Boston Scientific Sees 2Q Reported Sales Up 17.5%-19.5%, Organic Sales Up 13%-15% >BSX

23. apr 2025, 10:31 UTC

Tulu

Boston Scientific Sees 2025 Reported Sales Up 15%-17%, Organic Sales Up 12%-14% >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q EPS 45c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Adj EPS 75c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY Adj EPS $2.87-Adj EPS $2.94 >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Sales $4.66B >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees 2Q Adj EPS 71c-Adj EPS 73c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees 2Q EPS 45c-EPS 47c >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific 1Q Organic Sales Up 18.2% >BSX

23. apr 2025, 10:30 UTC

Tulu

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

3. märts 2025, 11:59 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3. märts 2025, 11:58 UTC

Omandamised, ülevõtmised, äriostud

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5. veebr 2025, 21:33 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 15:20 UTC

Tulu

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5. veebr 2025, 11:39 UTC

Tulu

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

Võrdlus sarnastega

Hinnamuutus

Boston Scientific Corp. Prognoos

Hinnasiht

By TipRanks

21.16% tõus

12 kuu keskmine prognoos

Keskmine 124.96 USD  21.16%

Kõrge 140 USD

Madal 112 USD

Põhineb 24 Wall Streeti analüütiku instrumendi Boston Scientific Corp. 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

24 ratings

23

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

102.95 / 104.93Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

No Evidence

Sentiment

By Acuity

136 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.